Age-related macular degeneration

References

• EhrlichRHarrisAKheradiyaNSWinstonDCiullaTAWirostkoBAge-related macular degeneration and the aging eyeClin Interv Aging2008347348218982917
   PubMed Web of Science ®Google Scholar
• NicklaDLWallmanJThe multifunctional choroidProg Ret Eye Res201029144168
   PubMed Web of Science ®Google Scholar
• ChenHLiuBLukasTJNeufeldAHThe Aged Retinal Pigment Epithelium/Choroid: A potential substratum for the pathogenesis of age-related macular degenerationPloS One20083e233918523633
   PubMed Web of Science ®Google Scholar
• ColemanHRChanCCFerrisFLChewEYAge-related macular degenerationLancet20083721835184519027484
   PubMed Web of Science ®Google Scholar
• SunKCaiHTezelTHPaikDGaillardERDel PrioreLVBruch’s membrane aging decreases phagocytosis of outer segments by retinal pigment epitheliumMol Vis2007132310231918199972
   PubMed Web of Science ®Google Scholar
• ZweifelSASpaideRFCurcioCAMalekGImamuraYReticular pseudodrusen are subretinal drusenoid depositsOphthalmology201011730331219815280
   PubMed Web of Science ®Google Scholar
• QuerquesGQuerquesLMartinelliDPathologic insights from integrated imaging of reticular pseudodrusen in age-related macular degenerationRetina20113151852621150696
   PubMed Web of Science ®Google Scholar
• YehoshuaZRosenfeldPJGregoriGProgression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomographyOphthalmology201111867968621035861
   PubMed Web of Science ®Google Scholar
• KleinRJZeissCEmilyYComplement factor H polymorphism in age-related macular degenerationScience200530838538915761122
   PubMed Web of Science ®Google Scholar
• RiveraAFisherSAFritscheLGHypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease riskHum Mol Genet2005143227323616174643
   PubMed Web of Science ®Google Scholar
• FritscheLGLoenhardtTJanssenAAge-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNANat Genet20084089289618511946
   PubMed Web of Science ®Google Scholar
• LevezielNZerbibJRichardFGenotype-phenotype correlations for exudative age-related macular degenerationInvest Ophthalmol Vis Sci20081422632271
   Google Scholar
• SchollHPFleckensteinMIssaPCKeilhauerCHolzFGWeberBHFAn update on the genetics of age-related macular degenerationMol Vis20071319620517327825
   PubMed Web of Science ®Google Scholar
• TakedaALColquittJCleggAJJonesJPegaptanib and ranibizumab for neovascular age related macular degeneration: A systematic reviewBr J Ophthalmol2007911177118217475698
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUMRichardGAugustinAGuidance for the treatment of neovascular age-related macular degenerationActa Ophthalmol Scand20078548649417655610
   PubMedGoogle Scholar
• RosenfeldPJDavidMBrownDMRanibizumab for neovascular age-related macular degenerationN Engl J Med20063551419143117021318
   PubMed Web of Science ®Google Scholar
• BrownDMMichelsMKaiserPKHeierJSSyJPIanchulevTRanibizumab versus verteporfin photodynamic therapy or neovascular age-related macular degeneration: Two-year results of the ANCHOR studyOphthalmology2009116576519118696
   PubMed Web of Science ®Google Scholar
• CohenSYDuboisLTadayoniRResults of one-year’s treatment with ranibizumab for exudative age-related macular degeneration in a clinical settingAm J Ophthalmol200914840941319477713
   PubMed Web of Science ®Google Scholar
• RegilloCDDavidMBrownDMRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1Am J Ophthalmol200814523924818222192
   PubMed Web of Science ®Google Scholar
• MeyerCHEterNHolzFGRanibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trialInvest Ophthalmol Vis Sci200849E Abstr 273
   Google Scholar
• Schmidt-ErfurthUEldemBGuymerREfficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE studyOphthalmology1292010 [Epub ahead of print]
   Google Scholar
• FungAELalwaniGARosenfeldPJAn optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degenerationAm J Ophthalmol200714356658317386270
   PubMed Web of Science ®Google Scholar
• LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO studyAm J Ophthalmol2009148435819376495
   PubMed Web of Science ®Google Scholar
• QuerquesGAzryaSMartinelliDRanibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional settingBr J Ophthalmol20109429229619951942
   PubMed Web of Science ®Google Scholar
• GowerEWCassardSDBassEBScheinODBresslerNMA cost-effectiveness analysis of three treatments for age-related macular degenerationRetina20103021222119940805
   PubMed Web of Science ®Google Scholar
• BashschurZFHaddadZASchakalARJaafarRFSaadANoureddinBIntravitreal bevacizumab for treatment of neovascular age-related macular degeneration: The second year of a prospective studyAm J Ophthalmol2009148596519375689
   PubMed Web of Science ®Google Scholar
• PatelSCombination therapy for age-related macular degenerationRetina2009296 SupplS454819553801
   PubMed Web of Science ®Google Scholar
• ChenEBrownDMWongTPLucentis using Visudyne study: Determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degenerationClin Ophthalmol201041073107920957143
   PubMedGoogle Scholar
• NiZHuiPEmerging pharmacologic therapies for wet age-related macular degenerationOphthalmologica200922340141019622904
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSMBrowningDJA phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degenerationOphthalmology20091162141214819700196
   PubMed Web of Science ®Google Scholar
• National Institutes of HealthSafety and efficacy study of small interfering ribonucleic acid (RNA) molecule (C and 5) to treat wet age-related macular degeneration Available at: www.clinicaltrials.gov. Accessed April 14, 2011.
   Google Scholar
• National Institutes of HealthA dose escalation trial of an intravitreal injection of Sirna-027 in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) Available at: www.clinicaltrials.gov. Accessed April 14, 2011.
   Google Scholar
• National Institutes of HealthSafety and efficacy of oral PTK787 in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) Available at: www.clinicaltrials.gov. Accessed April 14, 2011.
   Google Scholar
• DoukasJMaheshSUmedaNTopical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edemaJ Cell Physiol2008216293718330892
   PubMed Web of Science ®Google Scholar
• National Institutes of HealthOpen-label, pilot study of TG100801 in patients with choroidal neovascularization due to AMD Available at: www.clinicaltrials.gov. Accessed April 14, 2011.
   Google Scholar
• National Institutes of HealthA study to evaluate pazopanib tablets in patients who have neovascular age-related macular degeneration Available at: www.clinicaltrials.gov. Accessed April 14, 2011.
   Google Scholar
• Deal watch: Alcon licenses complement pathway inhibitor for macular degenerationNat Rev Drug Discov20098922
   Web of Science ®Google Scholar
• National Institutes of HealthA study of ARC1905 (anti-C5 aptamer) in subjects with dry age-related macular degeneration Available at: www.clinicaltrials.gov. Accessed April 14, 2011.
   Google Scholar
• National Institutes of HealthA Phase 1, safety, tolerability and pharmacokinetic profile of intravitreous injections of E10030 (anti-PDGF pegylated aptamer) in subjects with neovascular age-related macular degeneration Available at: www.clinicaltrials.gov. Accessed April 14, 2011.
   Google Scholar
• KuwadaSKDrug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibodyCurr Opin Mol Ther20079929817330407
   PubMed Web of Science ®Google Scholar
• TheodossiadisPGLiarakosVSSfikakisPPVergadosIATheodossiadisGPIntravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degenerationAm J Ophthalmol200914782583019211094
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research GroupA randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8Arch Ophthalmol20011191417143611594942
   PubMed Web of Science ®Google Scholar
• HuangLLColemanHRKimJOral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMDInvest Ophthalmol Vis Sci2008493864386918450596
   PubMed Web of Science ®Google Scholar
• RaduRAHanYBuiTVReductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: A potential therapy for treatment of lipofuscin-based retinal diseasesInvest Ophthalmol Vis Sci2005464393440116303925
   PubMed Web of Science ®Google Scholar
• National Institutes of HealthStudy of fenretinide in the treatment of geographic atrophy associated with dry age-related macular degeneration20071 http://clinicaltrials.gov/ct2/show/NCT00429936?term=fenretinide&rank=10 Accessed 19 April 2011.
   Google Scholar
• TanitoMLiFAndersonREProtection of retinal pigment epithelium by OT-551 and its metabolite TEMPOL-H against light-induced damage in ratsExp Eye Res20109111111420434439
   PubMed Web of Science ®Google Scholar
• WongWTKamWCunninghamDTreatment of geographic atrophy by the topical administration of OT-551: Results of a Phase II clinical trialInvest Ophthalmol Vis Sci2010516131613920574018
   PubMed Web of Science ®Google Scholar
• CurtisLHHammillBGSchulmanKACousinsSWRisks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degenerationArch Ophthalmol20101281273127920937996
   PubMed Web of Science ®Google Scholar
• JeganathanVSVermaSSafety and efficacy of intravitreal anti-VEGF injections for age-related macular degenerationCurr Opin Ophthalmol20092022322519367163
   PubMed Web of Science ®Google Scholar
• SingerMHorizon extension trial of ranibizumab (Lucentis®) for neovascular age-related macular degeneration (AMD): Two-year safety and efficacy resultsInvest Ophthalmol Vis Sci2009 E-Abstr 3093
   Google Scholar
• BoyerDSHeierJSBrownDMFrancomSFIanchulevTRubioRGA Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degenerationOphthalmology20091161731173919643495
   PubMed Web of Science ®Google Scholar
• LihtehWuMartínez-CastellanosMAQuiroz-MercadoHTwelve-month safety of intravitreal injections of bevacizumab (Avastin®): Results of the Pan-American Collaborative Retina Study Group (PACORES)Graefes Arch Clin Exp Ophthalmol2008246818717674014
   PubMed Web of Science ®Google Scholar